Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Analysis, By Non-invasive Test Type (Serology Test, Stool Antigen Test, Urea Breath Test), By Test Type (Laboratory-based Tests, Point-of-Care Tests), By End-user (Hospitals, Diagnostic Labs, Clinics) - Global Market Insights 2020 to 2026

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Overview:

The Helicobacter Pylori Non-Invasive Testing market is anticipated to register a moderate CAGR of 3.9% during the forecast period (2020-2026).

 Helicobacter Pylori infection, or H. Pylori, is the most prevalent bacterial infection, affecting the digestive tract and inner stomach lining. H. Pylori affects more than half of the world’s population. According to clinical findings, H. Pylori infection is the most prominent cause of dyspepsia, peptic ulcers and gastric adenocarcinoma.

Over the years, the incidence of H. Pylori infection has been declining. Adoption of non-invasive tests for diagnosing H. Pylori infection and subsequent treatment is rising among healthcare professionals. Availability of new and advanced non-invasive tests such as real-time PCR and Chemiluminescence Immunoassay (CLIA) are anticipated to leverage market prospects.

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Test-type Insights:

The urea breath test segment is set to capture a majority of the global H. Pylori Non-Invasive Testing market, pegged at more than two-fifth of the overall market. Excellent clinical sensitivity and high accuracy in detecting h. pylori are anticipated to boost market prospects. Projections have pegged the urea breath segment’s CAGR at 8.2% during the forecast period. The urea breath test is also useful for evaluation of post-treatment status.

Stool Antigen Tests are poised to account for the second-highest proportion of H. Pylori Non-invasive testing in the future. The simplicity and effectiveness in detecting bacteria are key drivers anticipated to raise the market prospects. The Stool Antigen Test segment shall account for more than 40% of the total H. Pylori Non-invasive testing market, expanding at a CAGR of 2.5%.

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Regional Insights:

North America is set to be the kingpin of the global H. Pylori testing market. This is attributed to changing healthcare reforms and implementation of guidelines by healthcare agencies regarding non-invasive testing of H. Pylori. These policies have redirected healthcare organizations and professionals to concentrate more on urea based testing and stool antigen tests.

This is because serology tests, the main type of test to detect presence of H. Pylori, provide false positive predicted value and cannot distinguish between current or past infections. In the wake of this, the North American market shall account for more than three-tenths of the global H. Pylori Testing Market.

Following North America is Asia-Pacific, poised to be leveraged moderately at a CAGR of 4.5%. Improvement in public health and creation of awareness are anticipated to contain the rate of H. Pylori infections during the forecast period. Testing for H. Pylori infection in communities with high incidence of gastric cancer is increasing, thus preventing further cases. More than one-fifth of the global H. Pylori testing market shall be held by the Asia-Pacific region.

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Manufacturers

Key Companies Profiled

• Meridian Bioscience Inc.
• DiaSorin S.p.A
• Alere
• Sekiusi Diagnostics and Biomerica Inc.
• Biohit Oyj
• Exalenz Bioscience Ltd.
• Aalto Bio Reagents Ltd.
• Certest Biotec S.L. 
• CorisBioconcept SPRL.

The global H. Pylori non-invasive testing market comprises of the following market players: Meridian Bioscience, Inc., DiaSorin S.p.A, Alere, Sekiusi Diagnostics and Biomerica, Inc. Besides these, a host of other players have a significant market presence as well. These are Biohit Oyj, Exalenz Bioscience Ltd., Aalto Bio Reagents Ltd., Certest Biotec S.L. and CorisBioconcept SPRL.

Meridian Bioscience, Inc. markets its tests and assay kits to hospitals, reference laboratories and other diagnostic manufacturers in more than 60 countries. Its H. Pylori testing products include the Premium Platinum HpSA PLUS or Premium H. Pylori. It is an in vitro qualitative procedure to detect the presence of H. Pylori bacteria in the human stool.

Exalenz Biosciences manufactures the H. Pylori IgG ELISA Kit, BreathID HP, BreathID Smart and Breath ID Lab devices. These devices conduct a quick and accurate Urea Breath Test for diagnosing H. Pylori infection and confirming post-treatment eradication. The test is conducted in real-time by continuously sampling breath, eliminating the need for sample collection, labeling, transport and analysis.

COVID-19 Market Insights:

Although there is a dearth of evidence suggesting any links between the COVID-19 and H. Pylori infections, experts have concluded that patients need to be provided treatment on a priority basis. This is because the COVID-19 infection affects the gastrointestinal tract, inducing nausea, vomiting and diarrhea. Since H. Pylori primarily infects the GI tract, it is important for those patients to be provided immediate medical attention if infected with the COVID-19. As the pandemic is spreading at an exponential rate, key manufacturers are accelerating their efforts to contain its spread.

This involves redirecting their resources towards developing COVID-19 testing kits. For instance, Meridian Bioscience has launched the QuickPac II 2019 COVID-19 IgG and IgM qualitative testing kit for the detection of potential antibodies to combat the novel coronavirus strain in the human serum, plasma or blood. Similarly, DiaSorin S.p.A announced the launch of its LIAISON SARS CoV-2 S1/S2 IgG serological test. Such developments are anticipated to shift focus away from H. Pylori testing, leading to a dip in its demand. However, patients requiring urgent care will be provided with the appropriate treatment.

Analyst’s Viewpoint:

The global H. Pylori non-invasive testing systems market shall record modest growth. Although the incidence of testing has burgeoned, the asymptomatic nature of the infection has limited its diagnosis. This is majorly responsible for the market’s moderate growth trajectory. Moreover, the ongoing coronavirus pandemic is anticipated to shift focus on eradicating the current disease, leading to a dip in h. pylori testing.

Global H. Pylori Non-Invasive Testing Market: Report Scope:

The recent report published by Fact.MR incorporates a six-year forecast period, ranging from 2020 to 2026, and elaborates on the key drivers, opportunities and restraints associated with the H. Pylori non-invasive testing systems market.

The study includes a detailed analysis of key segments’ revenue, market share and growth across the forecast period. The global h. pylori non-invasive testing systems market has been segmented based on non-invasive test type, test method and end-user.

An elaborate regional landscape has also been provided. This section incorporates an analysis of the abovementioned segments across North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. In addition, a section on competitive landscape has also been embedded within the report.

This part highlights key companies’ profiles, their revenue and market shares, key collaborations, product launches and SWOT analysis in order to provide a realistic picture about their future prospects.

Market Segmentation

Fact.MR has studied the global helicobacter pylori (h. pylori) Non-invasive testing market with detailed segmentation on the basis of Non-invasive Test Type, Test Method, End-user and key regions.

• By Non-invasive Test Type :

  • Serology Test
  • Stool Antigen Test
  • Urea Breath Test

• By Test Type :

  • Laboratory-based Tests
  • Point-of-Care Tests

• By End-user :

  • Hospitals
  • Diagnostic Labs
  • Clinics

• By Key Regions :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”